Company intelligence / Profile preview

AtheroMed

Menlo Park, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

AtheroMed developed the Phoenix Atherectomy System, a minimally invasive catheter-based device for treating peripheral artery disease. The Phoenix system was evaluated in the EASE clinical trial and received FDA 510(k) clearance in January 2014. The company was acquired by Volcano Corporation in mid-2014 for $115 million cash plus potential milestone payments.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, atherectomy catheter system)
Industry: Surgical Medical Devices

Partnerships

No major external pharmaceutical or biotech partnerships reported; post-acquisition, integrated into Volcano's portfolio

Beyond the preview

Go deeper on AtheroMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtheroMed.

Explore the full profile